Company intelligence / Profile preview
Heron Therapeutics, Inc.
Cary, North Carolina, United Statesherontx.com ↗
- Ownership
- Public · HRTX
- Development stage
- Other
01
Overview
Heron Therapeutics has successfully commercialized multiple products including ZYNRELEF for postoperative pain, CINVANTI for CINV, SUSTOL for CINV, and APONVIE for PONV. The company received FDA approval for ZYNRELEF Vial Access Needle in September 2024 and for a supplemental New Drug Application for ZYNRELEF in January 2024.
- Therapeutic areas
- GastroenterologyOncologyNeurology
- Modalities
- Extended-release drug formulationspolymer-based drug delivery
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
CrossLink Life Sciences
04
Financials
- Market cap
- $53.2M
- Total revenue
- $154.9M
- Enterprise value
- $158.8M
Beyond the preview
Go deeper on Heron Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heron Therapeutics, Inc..